Skip to content

The pharmacokinetics and pharmcodynamics of telmisartan tablet

The influence of MRP2, MDR1 and OATP1B3 polymorphism on telmisartan's pharmacokinetics and pharmacodynamics

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TNC-10000898
Enrollment
Unknown
Registered
2010-06-11
Start date
2010-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

A:After an overnight fast, the subjects ingested a single 40mg dose of telmisartan with 250ml water

Sponsors

Central South University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Healthy men, aged between 19~40y, and the age years difference among the subjects is no more than 10y in one trial; 2. Weight over than 50kg, and in the scope of +/-10% ideal weight; 3. Without gastrointestinal tracts diseases, liver or severely kidney injury; 4. Without supersensitive history on drugs, and without postural hypotension; 5. Take no medicine drugs in last two weeks before trials; 6. All subjects sign the written informed consent.

Exclusion criteria

Exclusion criteria: 1. Systolic blood pressure 100/min; 2. With the supersensitive history on drugs, and supersensitive with telmisartan; 3. Participated other clinical trails in last three months, or taken any other drugs in last two weeks; 4. With gastrointestinal tracts diseases, liver or severely kidney injury.

Design outcomes

Primary

MeasureTime frame
Blood drug concentration of telmisartan;

Countries

China

Contacts

Public ContactWei Zhang
yjsd2003@163.com+86 731 84805380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 10, 2026